Stay updated with breaking news from Session Title. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 16 new data abstracts from across its hematology/oncology development program will...
Investegate announcements from Diaceutics PLC, Presenting data on COVID impact on cancer at ASCO
Panel Session Title: Alzheimer Disease Panel Date and Time: Wednesday May 26th, 11:00 a.m. Eastern time (8:00 a.m. Pacific time) Presented by: Maxim Group LLC | Hosted by: M-Vest Moderated by: Dr. Jason McCarthy About INmune Bio, Inc. INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfuncti...
Share: Longer Term Data from the ALLO-501 Phase 1 ALPHA Study to be Presented Alongside Initial Data from the Phase 1 ALLO-501A ALPHA2 Study Separate Presentation to Include Safety and PK/PD Data on ALLO-647 Used in, Allogene's Proprietary Lymphodepletion Regimen ALLO-501A, Intended for a Potentially Pivotal Phase 2 Trial, Previously Granted FDA Fast Track Designation for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) Allogene to Host Virtual CD19 Forum to Review ASCO Datasets on May 19, 2021 at 2:30 p.m. PT/5:30 p.m. ET SOUTH SAN FRANCISCO, Calif. and PARIS, April 28, 2021 (GLOB...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in ... Allogene Therapeutics, Inc.April 28, 2021 GMT Longer Term Data from the ALLO-501 Phase 1 ALPHA Study to be Presented Alongside Initial Data from the Phase 1 ALLO-501A ALPHA2 Study Separate Presentation to Include Safety and PK/PD Data on ALLO-647 Used in, Allogene’s Proprietary Lymphodepletion Regimen ALLO-501A, Intended for a Potentially Pivotal Phase 2 Trial, Previously Granted FDA Fast Track Designation...